Endoscopic screening for gastric cancer: A cost‐utility analysis for countries with an intermediate gastric cancer risk
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Endoscopic screening for gastric cancer is debatable in countries with an intermediate risk. Objective: The objective of this article is to determine the cost‐utility of screening strategies for gastric cancer in a European country. Methods: We conducted a cost‐utility analysis using a Markov model comparing three screening strategies versus no screening: stand‐alone upper endoscopy, endoscopy combined with a colorectal cancer screening colonoscopy after a positive faecal occult blood test or pepsinogens serologic screening. Clinical data were collected from systematic reviews, costs from published national data and utilities as quality‐adjusted life years (QALY). The primary outcome was the incremental cost‐effectiveness ratio (ICER). Deterministic and probabilistic sensitivity analyses were performed. The threshold was set at €37,000 (2016 prices). Results: Upper endoscopy combined with screening colonoscopy (every 10 or 5 years) had an ICER of 15,407/QALY and €30,908/QALY respectively, stand‐alone endoscopic screening (every five years) an ICER of €70,693/QALY and pepsinogens screening an ICER of €143,344/QALY. Sensitivity analyses revealed that only endoscopic costs <€75, a provision of only three endoscopies per patient or a gastric cancer risk >25/100,000 would make stand‐alone endoscopic screening cost‐effective. Conclusion: Endoscopic gastric cancer screening in Europe can be cost‐effective if combined with a screening colonoscopy in countries with a gastric cancer risk ≥10 per 100,000.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Husereau, D., Drummond, M., Petrou, S., Carswell, C., Moher, D., Greenberg, D., Augustovski, F., Briggs, A. H., Mauskopf, J., & Loder, E. (2013) · Value in Health · doi:10.1016/j.jval.2013.02.002 · Cited by 1,998
The Role of Cost-effectiveness Analysis in Health and Medicine
Russell, L. B. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540140060028 · Cited by 1,167
Cited by
Pimentel-Nunes, P., Libânio, D., Marcos-Pinto, R., Areia, M., Leja, M., Esposito, G., Garrido, M., Kikuste, I., Megraud, F., Matysiak-Budnik, T., et al. (2019) · Endoscopy · doi:10.1055/a-0859-1883 · Cited by 993
Self-citationBanks, M., Graham, D., Jansen, M., Gotoda, T., Coda, S., di Pietro, M., Uedo, N., Bhandari, P., Pritchard, D. M., Kuipers, E. J., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318126 · Cited by 647
Self-citationRodríguez-Carrasco, M., Esposito, G., Libânio, D., Pimentel-Nunes, P., & Dinis-Ribeiro, M. (2020) · Endoscopy · doi:10.1055/a-1205-0570 · Cited by 69
“Although these programs can also be cost-effective in intermediate risk countries [59, 60], they have still not been implemented, and current recommendations suggest the diagnosis and surveillance of individuals with extensive preneoplastic conditions through the use of IEE [59, 61–63].”
BackgroundSelf-citation
Metadata
- Authors
- Areia, M., Spaander, M. C., Kuipers, E. J., & Dinis‐Ribeiro, M.
- Venue
- United European Gastroenterology Journal
- Publisher
- Wiley
- Published
- 2018-03
- Volume
- 6
- Issue
- 2
- Pages
- 192-202
- ISSN
- 2050-6406 (ISSN-L)
- 2050-6414
- OpenAlex
- W2738942565
- Cited by
- 110
- References
- 2
- FWCI
- 14.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endoscopic screening for gastric cancer: A cost‐utility analysis for countries with an intermediate gastric cancer risk. https://app.cochat.ai/papers/10.1177/2050640617722902
- The paper
- Areia, M., Spaander, M. C., Kuipers, E. J., & Dinis‐Ribeiro, M. (2018). Endoscopic screening for gastric cancer: A cost‐utility analysis for countries with an intermediate gastric cancer risk. United European Gastroenterology Journal. https://doi.org/10.1177/2050640617722902
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.